For the quarter ending 2025-09-30, SXTPW made $437,602 in revenue. -$2,316,324 in net income. Net profit margin of -529.32%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Product revenues net of discounts and rebates | 437,602 | 100,932 | ||
| Cost of revenues | 537,690 | 50,051 | ||
| Gross (loss) profit | -100,088 | 50,881 | ||
| Research revenues | 90,960 | 206,939 | ||
| Net (loss) revenue | -9,128 | 257,820 | ||
| Research and development | 809,777 | 249,884 | ||
| General and administrative expenses | 1,506,620 | 1,612,764 | ||
| Total operating expenses | 2,316,397 | 1,862,648 | ||
| Loss from operations | -2,325,525 | -1,604,828 | ||
| Interest expense | 1,708 | 1,221 | ||
| Change in fair value of derivative liabilities | 21,103 | 140,447 | ||
| Other income, net | 31,550 | 13,066 | ||
| Total interest and other income (expense), net | 8,739 | -128,602 | ||
| Loss from operations before provision for income taxes | -2,316,786 | -1,733,430 | ||
| Provision for income taxes (note 9) | 250 | 1,500 | ||
| Net loss | -2,317,036 | -1,734,930 | ||
| Net loss noncontrolling interest | -712 | -1,204 | ||
| Net loss attributed to 60 degrees pharmaceuticals, inc | -2,316,324 | -1,733,726 | ||
| Basic (in dollars per share) | -0.66 | -1.25 | ||
| Basic (in shares) | 3,675,407 | 1,472,891 | ||
| Diluted (in dollars per share) | -0.66 | -1.25 | ||
| Diluted (in shares) | 3,675,407 | 1,472,891 | ||
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)